Basic Information

Common name
Catalog number
ERBB2, CD340, HER-2, HER-2/neu, HER2, MLN 19, NEU, NGL, TKR1, VSCN2, erb-b2 receptor tyrosine kinase 2
Colon carcinoma
Tissue types
B-hHER2 CT26.WT cells have the capability to establish tumors in vivo and can be used for efficacy studies.


The mouse Erbb2 gene was replaced by human ERBB2 coding sequence in B-hHER2 CT26.WT cells. Human ERBB2 is highly expressed on the surface of B-hHER2 CT26.WT cells.

Targeting strategy

Gene targeting strategy for B-hHER2 CT26.WT cells. The exogenous promoter and human ERBB2 coding sequence was inserted to replace part of murine exon 2 and all of exons 3-7. The insertion disrupts the endogenous murine Erbb2 gene, resulting in a non-functional transcript.

Protein expression analysis

HER2 expression analysis in B-hHER2 CT26.WT cells by flow cytometry. Single cell suspensions from wild-type CT26.WT and B-hHER2 CT26.WT cultures were stained with species-specific anti-HER2 antibody. Human HER2 was detected on the surface of B-hHER2 CT26.WT cells but not wild-type CT26.WT cells. The 1-A03 clone of B-hHER2 CT26.WT cells was used for in vivo experiments.

Tumor growth curve & Body weight changes

Subcutaneous homograft tumor growth of B-hHER2 CT26.WT cells. B-hHER2 CT26.WT cells (1×105) and wild-type CT26.WT cells (1×105) were subcutaneously implanted into BALB/c mice (female, 7-week-old, n=6). Tumor volume and body weight were measured twice a week. (A) Average tumor volume ± SEM. (B)  Body weight (Mean± SEM). Volume was expressed in mm3 using the formula: V=0.5 X long diameter X short diameter2. As shown in panel A, B-hHER2 CT26.WT cells were able to establish tumors in vivo and can be used for efficacy studies.

Protein expression analysis of tumor cells

B-hHER2 CT26.WT cells were subcutaneously transplanted into BALB/c mice (n=6), and on 23 days post inoculation, tumor cells were harvested and assessed for human HER2 expression by flow cytometry. As shown, human HER2 was highly expressed on the surface of tumor cells. Therefore, B-hHER2 CT26.WT cells can be used for in vivo efficacy studies of novel HER2 therapeutics.

Back to top